Troglitazone A potent antiproliferative, apoptosis inducer, antioxidant, and antiinflammatory agent

Troglitazone (CAS 97322-87-7)

Troglitazone | CAS 97322-87-7 is rated 5.0 out of 5 by 1.
  • y_2019, m_5, d_22, h_2
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_200904, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 100ms
  • REVIEWS, PRODUCT
Application: A potent antiproliferative, apoptosis inducer, antioxidant, and antiinflammatory agent
CAS Number: 97322-87-7
Purity: ≥98%
Molecular Weight: 441.5
Molecular Formula: C24H27NO5S
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Troglitazone has been shown to be a potent antiproliferative and apoptosis inducer. This compound has displayed a capacity to inhibit growth of HCC cells via G1 phase cell cycle arrest through hypophosphorylation of Rb (retinoblastoma) protein and an increase of the cyclin-dependent kinase inhibitors, p21 and p27 proteins. In addition, Troglitazone has been reported to have profound antioxidant and antiinflammatory effects, and found to suppress L-type and receptor operated Ca2+ channel and PKC (protein kinase C). Experiments have shown Troglitazone to bind and activate PPARγ(peroxisome proliferator-activated receptor γ). PPARγ is mainly expressed in adipose tissue, one of the target tissues for insulin, but has subsequently been found to be expressed in vascular smooth muscle cells, endothelial cells, macrophages, and some cancer cells.


References

1. Tsubouchi, Y., et al. 2000. Biochem. Biophys. Res. Commun. 270: 400-405. PMID: 10753637
2. Okura, T., et al. 2000. Eur. J. Pharmacol. 407: 227-235. PMID: 11068018
3. Fujiwara, T., et al. 2000. Life Sci. 67: 2405-2416. PMID: 11065164
4. Aljada, A., et al. 2001. J. Clin. Endocrinol. Metab. 86: 3250-3256. PMID: 11443197
5. Berger, J., et al. 2002. Annu. Rev. Med. 53: 409-435. PMID: 11818483
6. Yoshizawa, K., et al. 2002. Cancer. 95: 2243-2251. PMID: 12412180

Physical State :
Solid
Solubility :
Soluble in ethanol (>25 mg/ml) at 50° C, DMSO (>25 mg/ml), DMF (30 mg/ml), DMSO:PBS (1:6, pH 7.2) (0.1 mg/ml), and water (0.1 mg/ml) at 25° C.
Storage :
Store at -20° C
Melting Point :
312.54° C (Predicted)
Boiling Point :
~657.0° C at 760 mmHg (Predicted)
Density :
~1.3 g/cm3 (Predicted)
Refractive Index :
n20D 1.61 (Predicted)
IC50 :
Stimulatin PPARγg glucose transport: EC5050 = 1 µM (adipocytes); PPARγ: EC5050 = 780 nM (murine); PPARγ: EC5050 = 555 nM (human); Induces cell cycle arrest and apoptosis: EC5050 = 10 µM (cancer cell lines); Monoamine oxidase B: IC50 = 2.07 µM (human)
Ki Data :
Peroxisome proliferator-activated receptor gamma: Ki= 3.8 µM (human)
pK Values :
pKa: 6.35 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
2
RTECS :
XJ5813130
PubChem CID :
5591
Merck Index :
14: 9769
MDL Number :
MFCD00878416
SMILES :
CC1=C(C(=C2CCC(OC2=C1C)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C)O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Troglitazone  Product Citations

See how others have used Troglitazone. Click on the entry to view the PubMed entry .

Citations 1 to 4 of 4 total

PMID: # 26313919  Myneni, VD. et al. 2015. Cell death & disease. 6: e1868.

PMID: # 24910239  Penner, N. et al. 2014. Drug Metab Lett. 8: 36-42.

PMID: # 22365411  Kim, Y. et al. 2012. Eur J Med Chem. 50: 311-8.

PMID: # 22981620  Kim, JA. et al. 2012. Toxicology letters. 214: 175-81.

Citations 1 to 4 of 4 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 94ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Yoshizakawa et al Yoshizakawa et al. (PubMed ID 12412180) showed that the PPRgamma ligand, troglitazone, inhibited the growth of hepatocellular cell lines via G1 phase cell cycle arrest and the induction of caspase-dependent apoptosis. -SCBT Publication Review
Date published: 2015-07-04
  • y_2019, m_5, d_22, h_2
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_200904, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 256ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.